Clicky

Molecular Templates, Inc.(MTEM)

Description: Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.


Keywords: Chemical Elements Cancer Solid Tumors Oncology Treatment Of Cancer Cancer Treatment Lymphoma Oxygen Serious Diseases Toxins Prodrugs Prodrug Evofosfamide Nitrogen Mustards

Home Page: www.mtem.com

MTEM Technical Analysis

9301 Amberglen Boulevard
Austin, TX 78729
United States
Phone: 512 869 1555


Officers

Name Title
Dr. Eric E. Poma Ph.D. CEO, Chief Scientific Officer & Director
Ms. Jason S Kim Pres & COO
Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer
Mr. Sean McLennan Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer
Ms. Megan C. Filoon Gen. Counsel & Sec.
Mr. Kurt Elster Exec. VP of Corp. Devel.
Dr. Jack Higgins Ph.D. Exec. VP of Operations & Head of Manufacturing
Dr. Erin Willert Ph.D. Exec. VP of R&D
Dr. Jen-Sing Liu Ph.D. Exec. VP of Manufacturing
Mr. Michael Dowd Sr. VP of Project & Alliance Management

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.9989
Price-to-Sales TTM: 0.7223
IPO Date: 2005-02-04
Fiscal Year End: December
Full Time Employees: 224
Back to stocks